Top 10 US Biotech Companies by Pipeline Value

The $100B market cap biotech with $13B revenue powered by Dupixent, the blockbuster eczema and asthma drug heading for $12B+ peak sales. Regeneron's antibody platform also produced world-class eye disease and cancer treatments.

The $110B market cap company that functionally cured cystic fibrosis with Trikafta, helping 90% of patients with $9B in revenue. Vertex is now applying the same precision medicine approach to pain, diabetes, and kidney disease.

The mRNA cancer vaccine pioneer with $4B revenue and Phase 3 trials underway for personalized cancer immunotherapy. BioNTech's Oxford partnership and pipeline of mRNA cancer vaccines represent a potential paradigm shift in oncology.

The $3B valuation company that achieved a historic milestone: Casgevy, co-developed with Vertex, became the first CRISPR-based cure approved by the FDA in December 2023 -- a one-time treatment for sickle cell disease.

The $2B valuation pioneer of in vivo CRISPR gene editing, delivering gene corrections directly inside the human body. Its NTLA-2001 program for transthyretin amyloidosis showed landmark results with a single infusion.

The $2B base editing pioneer co-founded by Eric Lander. Base editing corrects single-letter DNA errors without cutting the double helix, offering precision that standard CRISPR cannot match -- a platform applicable to thousands of genetic diseases.

The $4B AI drug discovery company with a landmark $50M NVIDIA partnership. Recursion has screened 2,000+ compounds using its biological foundation model, compressing the early-stage drug discovery timeline from years to weeks.

The synthetic biology platform company that programs cells like software. With a $1B valuation post-correction and 500+ customers, Ginkgo's cell engineering foundry is building the operating system for the biological economy.

The $800M cell engineering company pioneering fusosome delivery technology to insert therapeutic genes directly into target cells in the body. Sana is attacking blood cancers, genetic disorders, and autoimmune disease with its unique platform.

The $100B market cap biotech with $13B revenue powered by Dupixent, the blockbuster eczema and asthma drug heading for $12B+ peak sales. Regeneron's antibody platform also produced world-class eye disease and cancer treatments.

The $110B market cap company that functionally cured cystic fibrosis with Trikafta, helping 90% of patients with $9B in revenue. Vertex is now applying the same precision medicine approach to pain, diabetes, and kidney disease.

The mRNA cancer vaccine pioneer with $4B revenue and Phase 3 trials underway for personalized cancer immunotherapy. BioNTech's Oxford partnership and pipeline of mRNA cancer vaccines represent a potential paradigm shift in oncology.

The $3B valuation company that achieved a historic milestone: Casgevy, co-developed with Vertex, became the first CRISPR-based cure approved by the FDA in December 2023 -- a one-time treatment for sickle cell disease.

The $2B valuation pioneer of in vivo CRISPR gene editing, delivering gene corrections directly inside the human body. Its NTLA-2001 program for transthyretin amyloidosis showed landmark results with a single infusion.

The $2B base editing pioneer co-founded by Eric Lander. Base editing corrects single-letter DNA errors without cutting the double helix, offering precision that standard CRISPR cannot match -- a platform applicable to thousands of genetic diseases.

The $4B AI drug discovery company with a landmark $50M NVIDIA partnership. Recursion has screened 2,000+ compounds using its biological foundation model, compressing the early-stage drug discovery timeline from years to weeks.

The synthetic biology platform company that programs cells like software. With a $1B valuation post-correction and 500+ customers, Ginkgo's cell engineering foundry is building the operating system for the biological economy.

The $800M cell engineering company pioneering fusosome delivery technology to insert therapeutic genes directly into target cells in the body. Sana is attacking blood cancers, genetic disorders, and autoimmune disease with its unique platform.